|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Department of Health Sciences, University of Jyväskylä
Department of Health Sciences, University of Jyväskylä
Department of Clinical Chemistry, University of Oulu, Finland
Department of Clinical Chemistry, University of Oulu, Finland
Endocrine responses in seven power athletes were investigated during a 12 week strength training period, when the athletes were taking high doses of andro genic-anabolic steroids, and during the 13 weeks fol lowing drug withdrawal. During the use of steroids significant decreases (P < 0.05 to 0.001) in the serum concentrations of thyroid stimulating hormone, thyrox ine, triidothyronine, free thyroxine, and thyroid hor mone-binding globulin (TBG) were found, whereas the value of triidothyronine uptake increased (P < 0.001). In relation to the changes in the thyroid function param eters measured, we suggest that the primary target of androgen action was TBG biosynthesis. In five of the seven subjects, serum concentrations of growth hor mone increased at some point of the study 5 to 60- fold. Because of the use of exogenous testosterone, serum testosterone concentration tended to increase. This increase was associated with a corresponding increase (P < 0.001) in serum estradiol. Furthermore, there were major decreases in serum LH (P < 0.01) and FSH (P < 0.01) concentrations, and testicular tes tosterone production was therefore decreased. This was characterized by a very low serum testosterone concentration (5.1 ± 1.8 nmol/l) 4 weeks following drug withdrawal. Cessation of drug use resulted in return of all the variables measured to the initial values, except for serum testosterone, which was at a low level (14.6 ± 8.8 nmol/l) 9 weeks after drug withdrawal, indicating prolonged impairment of testicular endocrine function. No consistent changes were found in the eight control athletes.
This article has been cited by other articles:
![]() |
Z.'e. Hochberg, K. Pacak, and G. P. Chrousos Endocrine Withdrawal Syndromes Endocr. Rev., August 1, 2003; 24(4): 523 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Taylor, D. E. Brooks, and J. B. Ryan Anabolic-Androgenic Steroid Administration Causes Hypertrophy of Immobilized and Nonimmobilized Skeletal Muscle in a Sedentary Rabbit Model Am. J. Sports Med., November 1, 1999; 27(6): 718 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. King, R. L. Sharp, M. D. Vukovich, G. A. Brown, T. A. Reifenrath, N. L. Uhl, and K. A. Parsons Effect of Oral Androstenedione on Serum Testosterone and Adaptations to Resistance Training in Young Men: A Randomized Controlled Trial JAMA, June 2, 1999; 281(21): 2020 - 2028. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Bertovic, T. K. Waddell, C. D. Gatzka, J. D. Cameron, A. M. Dart, and B. A. Kingwell Muscular Strength Training Is Associated With Low Arterial Compliance and High Pulse Pressure Hypertension, June 1, 1999; 33(6): 1385 - 1391. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Bagatell and W. J. Bremner Androgens in Men -- Uses and Abuses N. Engl. J. Med., March 14, 1996; 334(11): 707 - 715. [Full Text] [PDF] |
||||
![]() |
H. A. Haupt Anabolic steroids and growth hormone Am. J. Sports Med., June 1, 1993; 21(3): 468 - 474. [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |